Kate Smith

Kate Smith is currently Principal Scientist, Development Services, at BioReliance, UK, part of the Merck Group. In this position, she is responsible for providing technical support to both colleagues and clients on the design, execution, and interpretation of viral clearance studies. Prior to transitioning into Development services Kate was responsible for managing the team involved in the preparation of cell banks, viral seeds stocks, and production of clinical lots of viruses.

Prior to joining BioReliance Kate was a Principal Group Leader in the Purification Development Group at Lonza Biologics, plc. She has more than 18 years of experience in the development, scale-up, transfer, and validation of purification processes for monoclonal antibodies and recombinant proteins from mammalian cell cultures. Her area of expertise is the design and management of Viral and DNA reduction studies used to support product safety.